CIK 0001840229
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MiNK Therapeutics, Inc.
Sign in to watch- Ticker
- INKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 212-994-8250
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
- 4 Grant or award Director acquired 10,688 shares (grant or award)
- 4 Grant or award Director acquired 11,737 shares (grant or award)
- 4 Grant or award Director acquired 13,550 shares (grant or award)
- 4 Grant or award Director acquired 13,646 shares (grant or award)
- 4 Open-market buy Director bought 20,000 shares at an average $1.38 ($27,646)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 5 Insider Annual Insider Trading Report
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 1,400,000 shares at $12.00 ($16,800,000)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 7 of 8 · 145 filings